Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Adenosine triphosphate (ATP)-guided pulmonary vein isolation (PVI) in comparison to conventional PVI did not reduce late recurrence atrial fibrillation (AF) at one year, according to the UNDER-ATP trial featured in the Atrial fibrillation/Pacing Hot Line session yesterday. The large-scale multicentre Japanese study was published simultaneously in the European Heart Journal.
Although radiofrequency catheter ablation has been developed as a curative therapy for AF, recurrent atrial tachyarrhythmias are estimated to occur in 30-40% of patients with paroxysmal AF, and 50-70% with persistent or long-lasting AF. Such recurrent atrial tachyarrhythmias are believed to be caused by electrical reconnections between the left atrium and pulmonary veins.
‘Radiofrequency ablation around the pulmonary veins can electrically block the connection but sometimes there are hidden gaps,’ explained Atsushi Kobori, the study presenter from Kobe City Medical Centre General Hospital, Kobe, Japan. ‘ATP is a chemical that can unmask dormant electrical conduction, therefore we used it after PVI to identify these gaps.’
Between November 2011 and March 2014, 2113 patients with paroxysmal, persistent, or long-lasting AF, recruited from 19 cardiovascular centres in Japan, were randomly assigned to either ATP-guided PVI (n = 1112) or conventional PVI (n = 1001), which involved extensive encircling PVI with use of an irrigation catheter.
After ablation, ambulatory ECGs were recorded twice daily for two weeks, with 24-hour ECG monitoring at hospital discharge, six months and one year. The primary endpoint was recurrent atrial tachyarrhythmias lasting for >30 seconds or those requiring repeat ablation, hospital admission, or antiarrhythmic.drugs at one year.
Results show that 68.7% of patients in the ATP-guided PVI group and 67.1% of patients in the conventional PVI group were free of the primary endpoint at one year (HR 0.89; 95% CI 0.74-1.09; P=0.25). The results were consistent across all the prespecified subgroups.
‘We found no significant impact of ATP on reducing late recurrences of AF,’ concluded Kobori. The findings were in direct contrast to three earlier studies demonstrating that ATP- guided PVI was of benefit. There may be several possible explanations for the discrepancy, wrote the authors in the EHJ, noting the fact that earlier studies were all retrospective and thus inherently associated with selection bias, and that comparisons were made with historical controls.
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
© 2017 European Society of Cardiology. All rights reserved